Alcon
As of the edition of 20 October 2026, Alcon runs 97 drugs, 64 of them marketed; it is on route A at 15 targets and on route B at 11 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 6 company names in this family.
- Aerie Pharmaceuticals: acquired in 2022; successor Alcon Research
Drugs by status
| Status | Count |
|---|---|
| Marketed | 64 |
| Active | 3 |
| Went quiet | 20 |
| Stopped | 7 |
| Status not established | 3 |
| Total | 97 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dexamethasone | none listed | 5 |
| Acetaminophen | none listed | 17 |
| Prednisolone | none listed | 6 |
| Sodium chloride | none listed | 0 |
| Moxifloxacin | none listed | 0 |
| Diclofenac | none listed | 7 |
| Triamcinolone acetonide | none listed | 3 |
| Ciprofloxacin | none listed | 0 |
| Phenylephrine | none listed | 6 |
| Timolol | none listed | 5 |
| Atropine | none listed | 12 |
| Dextrose | none listed | 0 |
| Brimonidine | none listed | 9 |
| Sodium bicarbonate | none listed | 0 |
| Calcium | none listed | 0 |
| Travoprost | none listed | 2 |
| Povidone-iodine | none listed | 0 |
| Tobramycin | none listed | 0 |
| Tetracaine | none listed | 0 |
| Magnesium | none listed | 0 |
| Brinzolamide | none listed | 3 |
| Brolucizumab | Ends 2031 (computed from the first US licence) | 0 |
| Potassium chloride | none listed | 0 |
| Pilocarpine | none listed | 2 |
| Fluorescein | none listed | 0 |
A route B row is one company at one target. 39 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 15 targets, route B at 11 targets.
All 26 rows on route A or B
In the product26 company-target rows on route A or B; 23 are not shown here, and no score is.
See all 26 targets where Alcon needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Eye: 83 trials led
- Immune system: 6 trials led
- Heart and blood vessels: 4 trials led